US 12,403,111 B2
Compositions and methods for treating neurodevelopmental disorders
Katherine Beebe, Salt Lake City, UT (US); Clement Y. Chow, Salt Lake City, UT (US); Mike Graglia, Mill Valley, CA (US); Marta Caceres Dahiya, Arlington, TX (US); Kathryn Helde, Seattle, WA (US); and Lindsay Wieczorek, Chaska, MN (US)
Assigned to SynGAP Research Fund, San Diego, CA (US); and University of Utah Research Foundation, Salt Lake City, UT (US)
Filed by SynGAP Research Fund, San Diego, CA (US); and UNIVERSITY OF UTAH RESEARCH FOUNDATION, Salt Lake City, UT (US)
Filed on Jan. 31, 2025, as Appl. No. 19/042,105.
Claims priority of provisional application 63/549,394, filed on Feb. 2, 2024.
Prior Publication US 2025/0248959 A1, Aug. 7, 2025
Int. Cl. A61K 31/197 (2006.01); A61P 25/08 (2006.01)
CPC A61K 31/197 (2013.01) [A61P 25/08 (2018.01)] 20 Claims
 
1. A method for treating a neurodevelopmental disorder comprising administering to a subject in need thereof a therapeutically effective amount of a compound of Formula (I):

OG Complex Work Unit Chemistry
wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, and R14 is each independently H or D; or a pharmaceutically acceptable salt thereof.